Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer

Lung Cancer

Volumn 41, Issue 2, 2003, Pages 131-143

  Pino, Irene ^a   Pío, Rubén ^a   Toledo, Gemma ^a   Zabalegui, Natalia ^a   Vicent, Silvestre ^a   Rey, Natalia ^a   Lozano, María D ^a   Torre, Wenceslao ^a   García Foncillas, Jesús ^a   Montuenga, Luis M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Bcl x; Heterogeneous ribonucleoprotein; Lung cancer; RNA metabolism; Splicing

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; ISOPROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOCALIZATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION;

EID: 0037491683     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00193-4     Document Type: Article

References (56)

1. Cooper T.A., Mattox W. The regulation of splice-site selection, and its role in human disease. Am. J. Hum. Genet. 61:1997;259-266.
2. Mazoyer S., Puget N., Perrin-Vidoz L., Lynch H.T., Serova-Sinilnikova O.M., Lenoir G.M. A BRCA1 nonsense mutation causes exon skipping. Am. J. Hum. Genet. 62:1998;713-715.
3. Hosokawa Y., Gadd M., Smith A.P., Koerner F.C., Schmidt E.V., Arnold A. Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Lett. 113:1997;123-130.
4. Sigalas I., Calvert A.H., Anderson J.J., Neal D.E., Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. 2:1996;912-917.
5. Sozzi G., Veronese M.L., Negrini M., et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 85:1996;17-26.
6. Oh Y., Proctor M.L., Fan Y.H., et al. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene. 17:1998;1141-1148.
7. Cheung N., Wong M.P., Yuen S.T., Leung S.Y., Chung L.P. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum. Pathol. 29:1998;910-914.
8. Dreyfuss G., Kim V.N., Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell. Biol. 3:2002;195-205.
9. Kim J.H., Hahm B., Kim Y.K., Choi M.Y., Jang S.K. Protein-protein interaction among hnRNPs shuttling between nucleus and cytoplasm. J. Mol. Biol. 298:2000;395-405.
10. Barnett S.F., Friedman D.L., LeStourgeon W.M. The C proteins of HeLa 40S nuclear ribonucleoprotein particles exist as anisotropic tetramers of (C1)3 C2. Mol. Cell. Biol. 9:1989;492-498.
11. Barnett S.F., Theiry T.A., LeStourgeon W.M. The core proteins A2 and B1 exist as (A2)3B1 tetramers in 40S nuclear ribonucleoprotein particles. Mol. Cell. Biol. 11:1991;864-871.
12. Smith C.W.J., Valcarcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem. Sci. 25:2000;381-388.
13. Chkheidze A.N., Lyakhov D.L., Makeyev A.V., Morales J., Kong J., Liebhaber S.A. Assembly of the alpha-globin mRNA stability complex reflects binary interaction between the pyrimidine-rich 3′ untranslated region determinant and poly(C) binding protein alpha CP. Mol. Cell. Biol. 19:1999;4572-4581.
14. Mitchell P., Tollervey D. mRNA stability in eukaryotes. Curr. Opin. Genet. Dev. 10:2000;193-198.
15. Michael W.M. Nucleocytoplasmic shuttling signals: two for the price of one. Trends Cell. Biol. 10:2000;46-50.
16. Nakielny S., Dreyfuss G. Transport of proteins and RNAs in and out of the nucleus. Cell. 99:1999;677-690.
17. Sweitzer T.D., Love D.C., Hanover J.A. Regulation of nuclear import and export. Curr. Top. Cell. Regul. 36:2000;77-94.
18. Habelhah H., Shah K., Huang L., et al. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat. Cell. Biol. 3:2001;325-330.
19. Michelotti E.F., Michelotti G.A., Aronsohn A.I., Levens D. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol. Cell. Biol. 16:1996;2350-2360.
20. Tomonaga T., Levens D. Activating transcription from single stranded DNA. Proc. Natl. Acad. Sci. USA. 93:1996;5830-5835.
21. Xu X., Joh H.D., Pin S., et al. Expression of multiple larger-sized transcripts for several genes in oligodendrogliomas: potential markers for glioma subtype. Cancer Lett. 171:2001;67-77.
22. Iervolino A., Santilli G., Trotta R., et al. hnRnp A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and Bcr/Abl leukemogenesis. Mol. Cell. Biol. 22:2002;2255-2266.
23. Zhou J., Allred D.C., Avis I., et al. Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res. Treat. 66:2001;217-224.
24. Yan-Sanders Y., Hammons G.J., Lyn-Cook B.D. Increased expression of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP) in pancreatic tissue from smokers and pancreatic tumor cells. Cancer Lett. 183:2002;215-220.
25. Matsuyama S., Goto Y., Sueoka N., et al. Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn. J. Cancer Res. 91:2000;658-663.
26. Tockman M.S., Mulshine J.L., Piantadosi S., et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin. Cancer Res. 3:1997;2237-2246.
27. Fielding P., Turnbull L., Prime W., Walshaw M., Field J.K. Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. Clin. Cancer Res. 5:1999;4048-4052.
28. Sueoka E., Goto Y., Sueoka N., Kai Y., Kozu T., Fujiki H. Heterogeneous nuclear ribonucleoprotein B1 as a new marker of early detection for human lung cancers. Cancer Res. 59:1999;1404-1407.
29. Sueoka E., Sueoka N., Goto Y., et al. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res. 61:2001;1896-1902.
30. Zhou J., Nong L., Wloch M., Cantor A., Mulshine J.L., Tockman M.S. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer. 34:2001;341-350.
31. Man Y.G., Martinez A., Avis I.M., et al. Phenotypically different cells with heterogeneous nuclear ribonucleoprotein A2/B1 overexpression show similar genetic alterations. Am. J. Respir. Cell. Mol. Biol. 23:2000;636-645.
32. Montuenga L.M., Zhou J., Avis I., et al. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. Am. J. Respir. Cell. Mol. Biol. 19:1998;554-562.
33. Ford L.P., Wright W.E., Shay J.W. A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation. Oncogene. 21:2002;580-583.
34. Hermann R., Hensel F., Muller E.C., et al. Deactivation of regulatory proteins hnRNP A1 and A2 during SC-1 induced apoptosis. Hum. Antibodies. 10:2001;83-90.
35. Brockstedt E., Rickers A., Kostka S., et al. Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J. Biol. Chem. 273:1998;28057-28064.
36. Kuhn H., Heydeck D., Brinckman R., Trebus F. Regulation of cellular 15-lipoxygenase activity on pretranslational, translational, and posttranslational levels. Lipids. 34:1999;S273-S279.
37. Mandal M., Vadlamudi R., Nguyen D., et al. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem. 276:2001;9699-9704.
38. Minoo P., Sullivan W., Solomon L.R., Martin T.E., Toft D.O., Scott R.E. Loss of proliferative potential during terminal differentiation coincides with the decreased abundance of a subset of heterogeneous ribonuclear proteins. J. Cell. Biol. 109:1989;1937-1946.
39. Biamonti G., Bassi M.T., Cartegni L., et al. Human hnRNP protein A1 gene expression. Structural and functional characterization of the promoter. J. Mol. Biol. 230:1993;77-89.
40. Zhou J., Mulshine J.L., Unsworth E.J., et al. Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J. Biol. Chem. 271:1996;10760-10766.
41. Kamma H., Portman D.S., Dreyfuss G. Cell type-specific expression of hnRNP proteins. Exp. Cell. Res. 221:1995;187-196.
42. Chabot B., Blanchette M., Lapierre I., La Branche H. An intron element modulating 5′ splice site selection in the hnRNP A1 pre-mRNA interacts with hnRNP A1. Mol. Cell. Biol. 17:1997;1776-1786.
43. Zhou J., Jensen S.M., Steinberg S.M., Mulshine J.L., Linnoila R.I. Expression of early lung cancer detection marker p31 in neoplastic and non-neoplastic respiratory epithelium. Lung Cancer. 14:1996;85-97.
44. Garayoa M., Man Y.G., Martinez A., Cuttitta F., Mulshine J.L. Downregulation of hnRNP A2/B1 expression in tumor cells under prolonged hypoxia. Am. J. Respir. Cell. Mol. Biol. 28:2003;80-85.
45. Stickeler E., Kittrell F., Medina D., Berget S.M. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene. 18:1999;3574-3582.
46. Caceres J.F., Stamm S., Helfman D.M., Krainer A.R. Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science. 265:1994;1706-1709.
47. Matter N., Marx M., Weg-Remers S., Ponta H., Herrlich P., Konig H. Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways. J. Biol. Chem. 275:2000;35353-35360.
48. Ghigna C., Moroni M., Porta C., Riva S., Biamonti G. Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res. 58:1998;5818-5824.
49. Minn A.J., Boise L.H., Thompson C.B. Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J. Biol. Chem. 271:1996;6306-6312.
50. Goto Y., Sueoka E., Chiba H., Fujiki H. Significance of heterogeneous nuclear ribonucleoprotein B1 as a new early detection marker for oral squamous cell carcinoma. Jpn. J. Cancer Res. 90:1999;1358-1363.
51. Bidot P., Morgan M., Zhukov T., Tannenbaum M., Tockman M.S. Loss of heterogeneous ribonucleoprotein A(2)/B(1) expression in thyroid neoplasms. Endocr. Pract. 7:2001;157-161.
52. Maeda T., Hiranuma H., Jikko A. Differential expression of the splicing regulatory factor genes during two-step chemical transformation in a BALB/3T3-derived cell line, MT-5. Carcinogenesis. 20:1999;2341-2344.
53. Kovar H., Jug G., Hattinger C., et al. The EWS protein is dispensable for Ewing tumor growth. Cancer Res. 61:2001;5992-5997.
54. Yang L., Embree L.J., Hickstein D.D. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol. Cell. Biol. 20:2000;3345-3354.
55. Perrotti D., Bonatti S., Trotta R., et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. Embo J. 17:1998;4442-4455.
56. Gouble A., Grazide S., Meggetto F., Mercier P., Delsol G., Morello D. A new player in oncogenesis: AUF1/hnRNPD overexpression leads to tumorigenesis in transgenic mice. Cancer Res. 62:2002;1489-1495.